Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 535 participants.
Also called NCT02864953
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 535 participants
- Sponsor
- Remedy Pharmaceuticals, Inc.
- Registry
-
NCT02864953 -
2017-004854-41
-
- Other papers using this trial's data
- Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Lithuania, Portugal, Russia, South Korea, Spain, Switzerland, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02864953. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-29 (actual); primary completion 2023-08-18 (actual). Results posted on 2024-01-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
- Acronym
- CHARM
- Condition
- Brain Edema
- Condition
- Stroke, Acute
- Intervention (Drug)
- BIIB093
- Intervention (Drug)
- Placebo
- Lead sponsor
- Remedy Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct02864953- Content hash
e73c9c1d28c5da525be8f14cabf56ab43fa5a51e6cc60866ce8caaf312716db5